Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Sinovac PCV24 in Adults
NCT06474377Phase 1Completed
- Sponsor
- Sinovac Life Sciences
- Start
- Jun 2024
- Primary completion
- Aug 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Sinovac PCV24 in pneumococcal disease (4 arms), sponsored by Sinovac Life Sciences. Primary endpoint: Incidence of adverse reactions. Started Jun 2024; status: completed.
02
Drugs
Sinovac PCV24
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT06474377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06474377.